Palliative radiotherapy in bladder cancer - importance of patient selection: a retrospective multicenter study
Song, Yee Pei
Logue, John P
Tran, Anna T
Wylie, James P
AffiliationDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M20 4BX, UK
MetadataShow full item record
AbstractOBJECTIVE: Investigate the effectiveness of palliative pelvic radiotherapy (PRT) in bladder cancer patients and identify factors associated with treatment outcome. MATERIAL AND METHODS: Patients with bladder cancer receiving PRT were identified retrospectively from two cancer centres between 2014 and 2017. Patients were stratified by age, stage, performance status, co-morbidities, previous chemotherapy, previous radiotherapy and radiotherapy protocol. Patients were followed up at 6 weeks after RT Median overall survival (mOS) from the last fraction of RT was calculated. Death within 30-days of RT or non-completion of treatment were considered as futile treatment. RESULTS: 241 patients were identified as receiving PRT A variety of RT protocols were used: 8Gy/1 fraction (11%), 21Gy/3 fractions (15%), 20Gy/5 fractions (18%), 36Gy/6 fractions (36%), 27.5-30Gy/8-10 fractions (18%). 38% of patients were of poor performance status (ECOG PS >/=3) and 46.5% had significant co-morbidities (ACE-27 >/=2). The mOS from the last fraction of RT was 153 days (0-1289 days). The 30-day mortality after radiotherapy was 18% (n=44) and incomplete planned radiotherapy treatment was 14% (n=33). First follow up information was available in 62% (n=150) of patients. Median time to this follow-up was 49 days (14-238 days). At first follow up about 6 weeks of last fraction of radiotherapy, patient symptoms were reported in 150 of 200 (75%) alive patients where 80 of 150 (53%) patients reported improvement in symptoms after treatment. There were significant differences in mOS with stage, performance status and co-morbidities. CONCLUSION: One in four patients either did not complete the planned RT course and/or died within 30 days of treatment. These patients were unlikely to have received maximal benefit from treatment but may have experienced side effects, making treatment futile. Patients with good performance status and earlier stage disease survived longer. Patient selection and comprehensive assessment are crucial in selecting appropriate patients for treatment.
CitationAli A, Song YP, Mehta S, Mistry H, Conroy R, Coyle C, et al. Palliative radiotherapy in bladder cancer - importance of patient selection: a retrospective multicenter study. Int J Radiat Oncol Biol Phys. 2019.
JournalInternational Journal of Radiation Oncology, Biology, Physics
- Clinical radiobiology of stage T2-T3 bladder cancer.
- Authors: Majewski W, Maciejewski B, Majewski S, Suwinski R, Miszczyk L, Tarnawski R
- Issue date: 2004 Sep 1
- Palliative radiation therapy of symptomatic recurrent bladder cancer.
- Authors: Yi SK, Yoder M, Zaner K, Hirsch AE
- Issue date: 2007 Mar
- Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the Radiation Therapy Oncology Group.
- Authors: Cox JD, Guse C, Asbell S, Rubin P, Sause WT
- Issue date: 1988 Dec
- Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study.
- Authors: Murthy V, Masodkar R, Kalyani N, Mahantshetty U, Bakshi G, Prakash G, Joshi A, Prabhash K, Ghonge S, Shrivastava S
- Issue date: 2016 Jan 1
- Retrospective study of palliative radiotherapy in newly diagnosed head and neck carcinoma.
- Authors: Stevens CM, Huang SH, Fung S, Bayley AJ, Cho JB, Cummings BJ, Dawson LA, Hope AJ, Kim JJ, O'Sullivan B, Waldron JN, Ringash J
- Issue date: 2011 Nov 15